|
| Primary information |
|---|
| ID | 10454 |
| Therapeutic ID | Th1081 |
| Protein Name | Antithymocyte globulin |
| Sequence | NA
|
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 62 (FAB fr |
| Half-life | 2-3 days |
| Description | Polyclonal rabbit anti-thymocyte globulin. Used to suppresses certain types of immune cells ascribed to acute organ rejection in transplant patients by selective depletion of T-cells. |
| Indication/Disease | For prevention of renal transplant rejection |
| Pharmacodynamics | Antithymocyte Globulin (ATG)is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. ATG is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation. ATG reduces the host immune response against tissue transplants or organ allografts. |
| Mechanism of Action | Binds to multiple, T-cell specific antigens leading to T-lymphocyte cell death via complement mediated cytotoxicity or apoptosis. |
| Toxicity | Not known whether ATG (rabbit) distributes into human milk; however, other immunoglobulins are distributed into human milk. |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production. |
| Absorption | T-cell depletion usually observed within 1 day after initiating therapy. Average 21.5 and 87 mcg/mL 4–8 hours post-infusion after first and last IV doses, respectively, when given for 7–11 days. |
| NA |
| Clearance | NA |
| Categories | Immunologic Factors and Immunosuppressive Agents |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Rilonacept results in increased immunosuppressive effects; increases the risk of infection |
| Target | NA |
| Brand Name | Thymoglobulin |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | NA |
| Useful Link 2 | NA |
| Remarks | NA |